The Royal Swedish Academy of Sciences has awarded Aaron Ciechanover, MD, DSc, the 2004 Nobel Prize in chemistry.
The Royal Swedish Academy of Sciences has awarded Aaron Ciechanover, MD, DSc, the 2004 Nobel Prize in chemistry.
Dr. Ciechanover, a scientist who receives funding from the Prostate Cancer Foundation, was recognized for his work on proteasome, a cellular machine that regulates the destruction of unneeded cell proteins. The proteasome is the target of the drug bortezomib (Velcade), which is being tested to treat prostate cancer and is approved to treat multiple myeloma.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.